Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
MFI2-AS1 enhances the survival of esophageal cancer cell via regulation of miR-331-3p/SOX4
Abstract
Purpose: To investigate the specific role of melanotransferrin antisense RNA (MFI2-AS1) in esophageal cancer (EC) progression.
Methods: The differential expression of MFI2-AS1 in EC tissues and cells was determined using quantitative reverse transcription–polymerase chain reaction (qRT-PCR). Silencing MFI2-AS1 was performed by transfection with specific short hairpin RNAs targeting MFI2-AS1. The 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) and flow cytometry (FC) were used to assess cell viability and apoptosis of EC cells, respectively. The sponging microRNA (miRNA) of MFI2-AS1 was validated using luciferase activity and RNA immunoprecipitation assays while the downstream target gene of the sponging miRNA was evaluated by luciferase activity assay.
Results: MFI2-AS1 was significantly enhanced in EC tissues (p < 0.01) and indicated a poor prognosis in EC patients. Knockdown of MFI2-AS1 in EC cells decreased cell viability and promoted cell apoptosis of EC cells. Functionally, MFI2-AS1 targeted miR-331-3p, and sex-determining region on Ychromosome-related high-mobility-group box4 (SOX4) was identified as a target gene of miR-331-3p. Ectopic expression of SOX4Â counteracted the suppressive effect of MFI2-AS1 knockdown on EC cell viability and stimulative effect on EC cell apoptosis.
Conclusion: The pro-oncogenic effect of MFI2-AS1 on EC progression occurs via the regulation of the miR-331-3p/SOX4 axis, providing a new potential therapeutic target for EC.
